NEW YORK (GenomeWeb) – Sygnis said this week that it has completed its acquisition of Innova Biosciences, a privately held UK-based bioconjugates company. Sygnis paid €10.8 million ($12.2 million), consisting of €8 million in cash and 2 million shares of Sygnis as a contribution in kind. Depending on agreed performance indicators, the purchase price will also include up to 1.5 million shares issued as convertible bonds. Innova develops, manufactures and commercializes labelling reagents, including its Lightning Link labeling technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.